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To determine the eNecu nl dopamkwl agonist therapy in 
.wvere bvoenen~ian. blood oressure. heat rate. rotecho,. 
sure >I20 mm Hg trange 124 to IMI) after intravenous 
fenoldopam therapy. Canstant inlesions of fenoldopam 
nerr titrated usward EYP~Y 10 to 20 min from an initial 
dose 010.1 &kg per min io B maximal dar do.9 &q 
per min. The therapeutic goat ol a supbir diastolic btwd 
pressure oi <ttO mm Hg was achiewd in every patient 
within I h at an werage dose of0.34 * 0.22 @kg pr min. 
BtoDd pressure derrearcd fram 2141134 2 33110 mm Hg at 
hawtine lo 170196 f; 2917 mm “g ,p < O.ooO,, at 3 h, 
whereas heart rate increased from 77 t 23 to 88 + 21 
beatslmin (p < 0.01). 
Fenoldopam mesylate (Smith, Kline & French. 82526-l) is a 
potent renal and systemic vasodilator that stimulates patsy- 
naphc dopamine receptors and is active both orally and 
parcnteratly (1). Unlike dopamme, fenoldopam lacks signif- 
icant alpha- or beta-adrmergic agonist activity (1.2). Thus, 
higher doses of fcnoldopam dl: :~ot dwctly increase either 
heart rate or blood pressure. Renal effects of this drug 
include an increase in urinary flow rate. free water cltarance 
and fractional excretion of sodium (j,Y). Srudics in animals 
Plasma norepinepbrine increased during the fenonnldo- 
nam infusion: er4nenhrine and dosamine levels did not 
the fenoldopam infusion, but mitrat Row veleeities during 
~m~trtcular filling were wehanged. Side effeetl of inlnve- 
now lenotdopam were mild, transient and wwtatd wttb 
the marked vDsoditstq pmpertta of the drug. 
Thus, fenotdopam b safe and efNt”e as a psrenterat 
manetherapy in patients with severe essatiat and remww 
cutar hypertension. Preliminary data suggest that btmd 
pressure rrdtiteo with ~tleettw dopnmbr-I sgenbt tbw 
spy is wampsnied by improved ton wntrtcutar fundion. 
(.J 4m CON Curdial 1988:11:1118-23) 
(5,6) suggest lhat dopamine-I receptllr stimulation may 
induce a direct tubular effect to enhance sodium excretion in 
addition to the diuresir that occurs through increased renal 
bload flow. 
Hemodynamic effects of fenoldopam in mildly hyperten- 
sive patients have been evaluated after oral dosing of the 
drug (7). Acutely, fenoldopam results in a decrease in blood 
presrure mediated by a reduction in total peripheral resis- 
tance. The reduction in peripheral resistance is associated 
with an increase in cardiac index, heart rate, stroke volume 
and left ventricular ejection rate. In addition, renal blood 
Row increases by 40 to SOW in hypertensive patients, 
whereas renal vascular resistace decreases by a similar 
amount after acute and short-term therapy with oral fenol- 
dopam (7.8). The findings of earlier studies with fenoldopam 
suggested that dopamine-I agonists would be an appropriate 
cla%s of drugs for hypertensive patients with renal insuffii- 
ctency or congestive heart failure. Recent pharmacokinetic 
study of intravenous adminisiration of fenoldapam 14) in 
hypertensive patients has shown that the drug n& an etimi- 
nation half-time of <IO min. The short plasma half-life of 
fenoldopam makes it ideal for parentersl we in rhe warnem 
of acute hypertension. 
In this study. we evaluated the effects of the parenter~i 
administration of fenoldopam in a variety of hospmdirci: 
patients with very severe or accelerated hypertenwm. in 
addition to the evaluarino of b!wx f p:“sxc rcipon,c .od 
side effect% leit ventricular function WIS asFessed by Dop- 
pler echocardiography. 
Methods 
hemodialysir unit at the Louisiana State University Medical 
Center. The protocols for this tudy were approved hy the 
Study patients. Eighteen patientc. aged 14 to l? yeart 
with severe or accelerated hypertension (supme dwtohc 
blood pressure >I20 nmm Hg) were \wdied during the acute 
phase of the protocol tscrecning and mfwionl m the medical 
intensive care unit at the University of Connecticut and the 
blond prewre WE maintained above 90 to 95 mm Hg. Rfter 
a mimmum oi 10 mm on a particular dose level. f*wkloni~rn 
war titrxcd upward hy 0.1 too.2 &kg per min ma maximal 
miuwm rate of I.5 @kg per min. Infusions oiienoldopam 
were then kept consxmr for 2 to 4 h after the goal diastolic 
bled p:wwe was achtevd Reiwe diwontinuing the iniw 
won. hiood chemistry values. urinalydr sod u.innry radium 
lercl\. and plasma catecholamine levels tConnecticut center 
onlvl wcrc measured and echocardiography tConnecticut 
center onlyl uas performed. Fluid inlake and urinary output 
were strictly measured during the infusion period. 
Fcnoldopam infusions were abruptly discmttinued m both 
centers. At Loutsiana State University Medical center. 
blood pwsure and heart mtc were iooitored every 2 to 5 
conventional oral or parenteral antthypertensive therapies 
were admimstered immediately before or at the dircontinuo- 
min ior 30 to Yo mm after discontinuation of rhe infusion znd 
tion of the mfusion: 81 the Universitv of Connecticut. the 
institutional review hoards of each mstmtti& and w&n raptd-acting oral agents were administered when the wpinc 
informed consent was obtained from all patients. Scieemng diartolic blood pressure we% >I20 mm Hg. Alter the infu- 
studies for entry into the protocol ;ncludcd hwory and sion. patients remained in the hospital for 3 days while blood 
nhysical examination. comolete blood couot. serum chemir- oress”re and heart rate were evaluated and broueht under 
try deterrrinations. urinalysis and urinary sodium analysis. 
chest X nv film, and I2 lead elecrrocardioaram IECGI. A 
minimumofthree supme blood pressure me&emems were 
taken within an hour of starting the ienoldopam mfuxon IO 
establish the baseline blond pressure. In one center Wniver- 
sity of Connecticut). digital subtraction arteriography was 
performed. if clinically appropriate, to exclude renovascular 
disease after the study. Antihypertensive medications were 
discontinued at the time of entry into the study and were 
withheld until the ienoldopam infusion was discontinued. 
Criteriafor exchoio~$vmz rhb sredy inalrrdcd: pregnancy 
or lactation, diastolic blood pressure > 170 mm Hg. acute 
myocardial infarction or crescendo angina pectorts. gheo- 
chmmocytoma. need for hcmodialyris or peritoneal dialysis. 
clinically apparent hypothyroidism and treatment with do- 
pamine antagonists (for example, phenothiarines. metoclo- 
pramide). 
lnlusion titration protocol. Alter scrsemng studmr, so- 
pine collection of plasma catecholamines (Connecticut cen- 
ter only) and urinary sodium (both centers) and combined 
Doppler and M-mode cchocardiography IConnecticut center 
only), a diluted solution of fenoldopam was administered at 
a constant infusion rate of 0. I &kg per min. Blood prerwre 
was monitored by means of an aotomated measuring devtce 
ICritikon Dinemapp unit) and confirmed with a mercury 
column. Heart ra;e~was continuously monitored wth star- 
dard ECG leads. The blood ore,ure and heart rate vere 
control and safety data were obtained (daily physical exam- 
inations. mrawrement of blood chemistry values. complete 
blood coum and ECGsl. Finally. 7 to 10 days after hospital 
discharge. patients were reevaluated in the clinics to assess 
the history and physical examinations. blood chemistry 
values and hematologic data. These snfcty d&a. including 
follow-up. were obtained in all 18 patients. 
Echocardiawaphy. Sector-guided Wmade echocardiog. 
raphy war performed by standard techniques using a Hew- 
lett-Packard system. A11 patients were imaged in the lcit 
lxeral decuhitus position from the left pancternal window. 
Left ventricular mass was calculated by the method of 
Rexhek and Devereux IIOI using the Penn mearurement 
convention\. laovolumic relaxation time. calculated by rub 
trxtion of the time from the R wave to aortic valve clowrc 
from the time from the R wave to mitml valve opening (I I). 
was recorded at a paper speed of 10x3 cm/s. and values fcr 
three to five consecutive cardiac cycles were averaged. Left 
ventricular and left atrial internal dimensions were measored 
usmg the leading edge methods according to the standards 
suggested by the American Society of Echocardiography 
t I?). Left ventricular(LV) fractional shortening was derived 
from the following formula: iLV internal dimension in dirs- 
tote - LV mternal dimension m systolellLV internal dimen- 
Jion in dtastole. 
Doppler eehorardiography. Mitral Row velocity was in- 
terroEilted usine a 1.25 MHz continuous wave transducer 
obtained at 2. 5 and IO min after any change in fenoldopam placed at the czzrdiac apex 1131. Mitral peak Row velouties 
dosing and evw 10 min during maintenance iniuion. The were mcawred in early diabtok (E wave) and late diasrole (A 
goal oi therspy war reduction of supine diastolic blood WLIYC:: three to five consecutiw bats were avenged. All 
prebare to it IO mm He or by 40 mm Hg II the barclinc Doppler ilnd M-mode echocardiograms were coded and read 
supine diastolic blood prerure was > I50 mm Hg. Diartolic by an expcnienccd echocardiognpher (M.J.R.). who was 
Time. m,ruter Figure 2. Blood prerrure and bean rate immediately after dacon- 
timation of inlrmenaur le”oldopam in to padents. No down 
Figur. 1. Effec!s of inwavenou~ fcnoldopam on blood prewre titralion was performed. Ord agents were administered when dia- 
(BP) dunnp tilmtton and maintenance phases for up to 3 h. Average slolic blood pressure exceeded I20 mm Hg after stopping the 
dare IU rchwe goal dias!olx blood presswe was 0.34 * 0.22 &kg mforion. t*p c 0.05. *‘p < 0.02. **‘p < O.wt. 
per min. 
dimensnons. movoluroic relaxation time. fractional shanen- 
iog, peak Row velocities and the A/E ratio were compared 
statistically at baseline and after 3 h of fenoldopam therapy 
using a two-tailed paired I test. 
Plasma catecbolamiw. Venous blwd samples for catc- 
choLlmine dctcrminations were collected at haseline from an 
indwelling heparin lock after the patient had been at wt and 
supine for 45 min. Subsequent samples were drawn after 2 b 
of mau~ienance fenoldopam therapy (or about 3 h of total 
infusion time). Plasma dopamine. epinephrinc sod norepi- 
nephrmc levels were determined by high performance liquid 
chromatography and electrochemical detection (14). 
Resufts 
Palient characteristia. Eighteen patients were studied at 
the two centers. There were I4 men and 4 women ranging in 
age from 34 to 72 years. Ten p.xnds who underwent renal 
digital subtraction arwriography had renal afiery stenosis (4 
patiemn) or nephrosclemsis (10 palientr) or both; baseline 
serum creatmine was bl.5 mcldl in seven of these oatients. 
Four patients were admitted to the study with ‘rebound 
hypenension asaoiiated with abrupt withdrawal from aloha- 
2 agonist therapy. 
Blood pressure and heart rate data. The blood orc~surc 
was reduced by It/t4 mm Hg at the initial dose of d.1 &kg 
per min tp < 0.01 for systolic: p < O.Wt for diastolic) and 
most patients reached the goal supine diastolic blood pres 
sure a! a dose of 0.3 to 0.4 &kg per min (Fig. I!. Heart rate 
increased significantly from 77 to 89 beatslmin (p < 0.01) at 
0.3 wkg per min. 
A progressive. smooth reduction in blood pressure was 
observed over the first 60 min of the fenoldopam infwon 
(Fig. I). Blood pressure was reduced from X4/132 to 1701% 
mm Hg after Ki min of therapy. There were no instances of 
“overshoot” hypotension and all 18 patients achieved the 
goal of thempy. The average dose of intravenous fenoldo- 
pam required to thieve the goal diastolic blood preswre 
was 0.34 ? 0.22 /rglkg per min. 
At one center (University of Connecticutl, fenoldopam 
was discontinued abrumlv and the blood ore~~ure and heart 
wtf responses were observed without additional therapy 
until the diastolic blood pressure was >I20 mm Hg. Blood 
pressure began to increase within 5 min of discontinuing the 
infusion and 8 of the 10 patients had diastolic blood oressure 
levels 2120 mm Hg &thin 30 min (Fig. 2). H&t rate 
became progressively lower during the first 30 min after 
cessation of administration of the drug. Rebound hyperten- 
sion above baseline values wal not observed. Blood prer 
sure reduction in individual patients wilh various standard 
classes of drugs (for example, labetalol. hydralazine, capto- 
ptil) was as expected; potentiation of there agents from 
residual effects of fenold-pam was not seen (data not 
shown). 
Plasma entecholamines. Catecholamines were assessed in 
IO of the patients. Plasma epinephrine and dopamine con- 
centrations did not change after fenoldopam theraw teoi- 
nephrine, 36 t 32 &ml at baseline to 39.2 34 pglmibu& 
fenoldopam; dopamine, <IO pg/ml at baseline and < IO pgiml 
during fenoldopam). Plasma norepinephrine levels increased 
significantly from 362 * 222 pgiml at baseline to 550 r 381 
pglml after fenoldopam therapy (Fig. 3). Parients with reflex 
tachycardia had the largest increases in plasma norepinrph- 
rine: however. because of the small number of subjects, a 
significant relation between change in heact rati and plasma 
norepinephrine levels could no1 be established. 
Urinary volume and sodium levels. Dota on urinary so- 
dium excretion were avnilable for 15 patients. An avenge 
diurcsis of 195 r 320 ml occurred during the fenoldopam 
infusion (range I20 to 880 mll. Fractional excretion of 
sodium increased from 0.86 c 0.64?4 at baseline to 1.77 e 
0.80% by the end of infusion (p < O.OI). Spcciiic gravity of 
theurine decreased from LOl6at baseline to I.UO9ar the end 
of infusion (P z 0.05). 
Fxbocardiegrapldc tindin@ (Tat& 1). Nine of the IO 
paired echocardiograms were of sufficient quality to assess 
the effects of fcnoldopam therapy. Five paired echocardio- 
grams were of sufficient quality to a5scss isovolumic rclax- 
ation time. Tbe left ventricular mass was 235 f 159g (normal 
range 110 to 180). Left atrial dimension. left ventncular 
dimension at diastole, fractional sbortenine and peak Row 
velocity during early and late diastolic filling did no* change 
after fenoldopam therapy. End-systolic dimension decreased 
Tsbk 1. Variables of Lcfl Ventricular Function During 
Fenoldopam Infusion in Nine Patients Wth Pawed 
Ecbocardiogams 
Bldre After 
I”f”V”” ,“f”Y,“” 
LA size @ml, 11.8 i v I II.3 T I!.? 
kanctmilal Ihoncnlng (pa) 42.7 r I0.I 47.7 f I, 5 
EnddiarlDUr dlmmrio” ,mro> il.1 t 4 7 48.0 ? ( 9 
End-ryrtOliL dilllellio” klla, 1s 0 > 6 5 1’) b z b P. 
PIaL “cloclly MS, 
*,“a, syllole “Xl?,,?, I,*,:“?, 
Early dlawhc 6umg 1fi7f011 I,,~:“.?2 
AIE ratio i 14 i ” :” I ,I T 0 57 
from 35 ? 7 mm at baseline to 28 2 6 mm during mainte- 
nance fcnoldopsm infusion; isovolumic relaxation time @or- 
rected for heart rate) decreased from I .Ol t 0.63 to 0.56 -i 
U.36 msibeztslmin (Fig. 41. 
Adverse side effects. There were no serious side etkcts in 
the entire patient group. Hence, no infusions were discon- 
tinued prematurely. The side effects observed were flushing 
(fOUr p2!ient$. Sy”IptorW,tK I” One,. PalpitallOnS ,tWo 
patients). unifocal ventricular cctopic acrivity (one patient), 
minor T-wave changes on the ECG (one patient) and head- 
ache (one patientl. Side effects were resolved after 30 to 60 
min of dircontinualion of the infusion. No abnormalities 
wsrc detected in the hernatologic or chemistry studies cval- 
uated at I, 2 or 7 days after fcnoldopam. 
Dkcussion 
Principal findings. The results of this study show that 
intravenous administration of fenoldopam. a new dopamme- 
I receptor agonist, decreased blood pressure in a variety of 
paucnts wth very severe or wxelerated hypertension. Fur- 
thermore, fenoldopam was well tolerated and did not cause 
cxccssivc hypotcnsion when admimstercd by conctant infu- 
sion. After discontinuation of the drug. blood pressure 
rapidly increased toward baseline level but did not rebound 
to exceed baseline blood pressure values. The most consist- 
cm side effects offcnaldopam were those associated with the 
agent’s vascdilbtory properties (for example. flushing and 
increased heart rate). 
Previous phamrdogic rtudiks with fenddopam. The ef- 
fectc of oral (7.8) and intravenous I IS) fcnoldooam ib! bvoer- 
I”R1‘ ,mr, 67 1 2 I 6 34.4 * xl+ tcnsive pat~erds~ include stimulation of specific dapkdne 
‘p< rJ.ol.+p<o.m. ME = rlilal\)\i”lulcnl> ,,,l,ng.lYRT = I,O”“IU.IC receptors in the renal vasculature that result in vasodilation. 
rebxalrn dim: LA = M iltnum In normoten~~ve patients. blood pressure and heart rate are 
nor appreciably s&ted by fenoldopom tX!. In our wdy of 
severely hypcrtcmive patxnt\. intnwcnow fenoldopom in- 
duccd marked reduction in blood prcrwre at low infusion 
raw Thw rcwlts add suppon to prewoub coocIu\iun5 
(7.R.161 that reduced dopammergic ac;ivoy cxpreracd at the 
vascular dnpamine-I rcccptor may contribute in part 10 the 
pathogcncn or maintenance of elevated blood prcswrc in 
esxnlial hypertension. 
Fcnoldopam administrauon produced a modest increhw 
in bar! rate in our partems with a significant increase in 
plasma norepmepbnnc (Fng. 3). Thee findings are in partial 
cootrail~t to the r~pnrl of Ventura et al. (71. who demon- 
strated a slgniticant increase in hean rate and cardiac output 
unaccompanied hy a change in plasma norepinephrine after 
an oral dose offcnoldopam. but are m concordance with the 
dam of Murphy et al. (IX who utilized intravenous fenol- 
dooam m mdd hvoenension. The increase in olasma noreo- 
inephrine arsc&ed with Ihc vasodilatory ‘propenies br 
fenoldopam IS not unlike that of other vasodiiators such as 
hydralarine (17) or nitrcnd!pine (IS). The increased sympa- 
thetic stimulntion associated with fenoldopam is also prob- 
ably rcsponsable for the minor T-wave changes and in- 
crcascd ventricular ectopic activity noted in two of our 
o&nts because these abnormalitica *ere absent on ECGs 
laken within I h of discontinuing the drug infusion. 
Renal function studies. A clinicidly siEnificant diwcsir of 
qploximately 400 ml in 3 to 4 h occurred during the drug 
in’usion. Because no patient m this study received diuretics 
immcdlatcly bcforc or during the infusion. it i: assumed that 
this “diuwis” was a result of increased renal perfusion 
during fenoldopam therapy. The observed increase in so- 
dium excretion during the infusion of fenoldooam in our 
severely hypenenswe~study group is consistent’with previ- 
ously reponed effects of fenoldopam in normal and mildlv 
hyp&ensive patients (3.15.19). in those studies, in which 
subjects were waler loaded. oral or mwwenou fenoldopam 
induced h dose-related oafurcsis in association with n 50% 
increase in renal plasma Row. The conditions of these 
studies were o&ditTerent from ourc because they were 
paformed in individuals who we!c carcful!v monitored for 
sodium and volume intake before the Rnoldopam dosing. 
0~ hypertensive study group was admitted dlrcctly ta the 
hospital. with no prior resw~clioos io sodium intake and no 
wner lo;idmg. and many had abnormid renill funclion. 
Sim&x duesir after iotrnveoouc administration offenoldn- 
pam hna been reported in B revercly hypertensive population 
by wwigators in Spain 1201. 
Fxbocardiagraphic data. Of particular interest were the 
elects of mlrweoou~ fcnoldopam on left ventricular petfor- 
mancc. The echocardiographic data demonwatc modest 
improvement in left ventricular function arrociated with a 
rcdwion in left ventricular end-ay\tolic dimension poaaibly 
accondary to ventricular unloading. Uiastolic performance 
was improved in three of the five patients in whom ~sovoIu- 
mic rela.wtion lime ua\ mcarurablc. The isovolumic relax- 
ofion tone i< incrcacd in hvoertcnsive oatients and corrc- 
t.111~ well wilh rapid left &lriculx f;llinp measured by 
radionuclide-derived Lime-activity curves (IO). Improvement 
in the wwolumic relaxation time may also be due in pan 10 
the reduced end-systolic volume or improved myocardial 
energebcs associated with reduced wall tension from after- 
load reduction. 
Invo+ve hemodynamic studies in severely hyperlcnsive 
patients after fcnoldopam therapy have oat ye! been rc- 
goned. In patients with congestive heart failure (21). oral 
fcnoldopam signdicantly decreases systemic vascular resis- 
tance and increases cardiac index but apparently ha, little 
effect on puln~onary vascular resistance or p&ad. Whether 
dopamine agonist therapy has positive inotropic effccls or 
increases myocardial contractility in patients with hyperten- 
sive heart disease remains to be determined. 
Clinicat significance of the findings. Coos&ml infusion of 
fcnoldopam induces a prompt, smooth reduction in blood 
pressure without serious side effects. Rapid. but not abrupt, 
reduction in blood pressure is indicated in most patients with 
severe or xc&rated hypertension. The reduction in blood 
prescore by intravenous fenoldopam is often associated with 
a clinically imporwt diuresis. obviating the need for a loop 
diuretic. Thus, the future of therapy with selective dononinr 
agonists may be in the treatment of hypertensive patients 
wit? excessive blood volume. including those with heart and 
renal failure. 

